drugset / Trial / NCT02125266

Safety and Preliminary Efficacy Study of V404 PDS in Uveitis

NCT02125266 ↗

Phase 1/2 Terminated 7 enrolled Forsight Vision4
RandomizedParallel-groupSingle-blindTreatment

Summary

This study is intended to evaluate the safety of V404 PDS in patients with chronic non-infectious uveitis. Secondarily, the study will evaluate whether V404 PDS can provide clinically measurable benefit over an extended period of time in patients with chronic non-infectious uveitis.

Timeline

Start
2014-04
Primary completion
2014-10
Completion
2015-03

Outcome

Outcome not reported

Stopped: “Study terminated due to unacceptable frequency of drug related adverse events”

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 0.6 mg Intravitreal
Subject Methotrexate Small molecule 2.3 mg Intravitreal